GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.
Healthcare & Pharmaceuticals
Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the first Phase 3 study to show a notable increase in event-free survival in the early stages of head and neck squamous cell carcinoma when using […]
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.
The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]
Rapid weight reduction might raise the risk of osteoporosis and reduce muscular mass. However, there is now excellent news for those who may be at danger when taking weight loss medications. According to a recent study from Aarhus University, the adverse effects can be mitigated by the medication bimagrumab.
PD-1 inhibitors and other immune checkpoint inhibitors can be used to treat dozens of different forms of cancer.